source
- GSK launches three-year £1.9bn savings plan to boost late-stage R&D and relocate research HQGSK announced a three-year cost-saving programme designed to free cash for its late-stage research and development pipeline while moving its research headquarters. The plan targets annual savings…
- Incyte drops phase-1 JAK2 inhibitor to focus on next-generation candidatesIncyte announced it is abandoning its phase-1 JAK2V617F inhibitor, INCB160058, which was being tested in patients with myeloproliferative neoplasms. The decision was disclosed in the company's sec…